Advertisement
BRKR vs DHR
Which Stock Would AI Choose? Bruker Corporation (BRKR) vs. Danaher Corporation (DHR) Stock Comparison
Key Takeaways
- Bruker Corporation (BRKR) is a mid-cap maker of scientific and analytical instruments; Danaher Corporation (DHR) is a large-cap diversified life sciences and diagnostics conglomerate.
- Bruker has rebounded sharply from its 2025 trough but remains volatile, carries elevated short interest, and posts a trailing loss; Danaher offers steadier fundamentals and meaningful free cash flow.
- Danaher is benefiting from recovering bioprocessing orders, the Masimo acquisition, and a new AI collaboration with NVIDIA; Bruker is still navigating a cautious academic and government funding environment.
- Both companies operate in life science tools, but they differ sharply in scale, diversification, valuation, and risk profile.
Introduction
Investors comparing BRKR and DHR are weighing two very different profiles within the same broad life science tools sector. Bruker Corporation is a focused, mid-cap developer of scientific instruments, while Danaher Corporation is a diversified industrial conglomerate built on acquisitions and recurring consumables revenue. This stock comparison is relevant to growth-oriented traders evaluating a higher-beta turnaround story against a more defensive, cash-generative franchise. Understanding their relative performance, market positioning, and catalysts helps clarify which profile may better suit current conditions.
BRKR Overview and Recent Performance
Bruker Corporation develops and manufactures high-performance scientific instruments and analytical and diagnostic solutions spanning life science research, applied markets, and in-vitro diagnostics. The company experienced a difficult 2025, with management lowering guidance amid weak U.S. academic and government demand and softness in biopharma and industrial research. In recent weeks, however, shares have recovered sharply from earlier lows, reflecting improving order momentum, an expected step-up in operating margin for 2026, and more constructive analyst coverage that includes several upward price-target revisions. Despite this rebound, Bruker trades below its 52-week high, reports a negative trailing earnings per share (EPS) figure, and carries a relatively high short interest as a percentage of float, indicating that market participants remain divided on the durability of the recovery.
DHR Overview and Recent Performance
Danaher Corporation operates through biotechnology, life sciences, and diagnostics segments, using its Danaher Business System framework to acquire and improve businesses with recurring revenue streams. Recent performance has been steady rather than spectacular: second-quarter revenue rose about 5.5% year over year, adjusted EPS increased roughly 8%, and core revenue grew in the low single digits. Life sciences posted its strongest quarter in several years, while bioprocessing orders grew at a mid-teens pace. The company also completed its roughly $9.8 billion acquisition of Masimo, a patient-monitoring technology firm, and announced an AI collaboration with NVIDIA focused on autonomous science. Analysts have responded with a series of price-target increases, though Danaher's premium valuation means the shares are pricing in a recovery that has not yet fully materialized.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page curates the platform's most compelling automated strategies. Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, yet only a select group earns placement in this featured section based on their suitability for current market conditions. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the set of tickers they monitor, so the section offers a practical way to survey options rather than sifting through the full catalog. Exploring the page can help traders identify approaches aligned with their own objectives and risk tolerance.
Head-to-Head Comparison
The core contrast between these two stocks is scale and stability. Danaher's roughly $160 billion market capitalization, diversified portfolio, and recurring consumables model provide a more defensive, cash-generative foundation, while Bruker's roughly $10 billion market cap and instrument-centric business make it more sensitive to capital-equipment spending cycles and funding trends. On growth drivers, Danaher is positioned around bioprocessing recovery, molecular diagnostics, and AI-enabled laboratory workflows, whereas Bruker's outlook hinges on a rebound in academic, government, and semiconductor-related demand. Risk factors differ as well: Bruker faces margin-execution uncertainty and elevated short interest, while Danaher carries integration and financing considerations tied to Masimo alongside a premium forward valuation. In terms of market sentiment, both have drawn recent analyst upgrades, but Danaher's broader, steadier earnings base contrasts with Bruker's higher-beta turnaround profile.
Tickeron AI Verdict
Based on observable factors such as trend consistency, cash-flow stability, diversification, and identifiable catalysts, Tickeron's AI would likely lean toward Danaher as the more favorably positioned name in the current environment. Danaher's recurring revenue model, recovering bioprocessing order trends, and steady analyst support suggest a more consistent trajectory, even though its valuation already embeds much of the anticipated recovery. Bruker's improving bookings and margin outlook make it a higher-upside but higher-risk candidate, with greater sensitivity to academic funding and execution. The AI's assessment is probabilistic rather than definitive, reflecting the distinct trade-off between Danaher's relative stability and Bruker's more volatile growth potential.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRKR is a StrongBuy and DHR is a StrongBuy.
BRKR in upward trend: 10-day moving average crossed above 50-day moving average on November 04, 2026
The 10-day moving average for BRKR crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 66 cases where BRKR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on BRKR as a result. In 68 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for BRKR just turned positive on November 04, 2026. Looking at past instances where BRKR's MACD turned positive, the stock continued to rise in 31 of 44 cases over the following month. The odds of a continued upward trend are 70%.
BRKR moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +14.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where BRKR advanced for three days, in 197 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BRKR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
BRKR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.923) is normal, around the industry mean (4.142). P/E Ratio (-87.586) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.070) is also within normal values, averaging (11.253). Dividend Yield (0.003) settles around the average of (0.011) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. BRKR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRKR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for DHR turns positive, indicating new upward trend
DHR saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 57 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 63%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where DHR advanced for three days, in 179 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 111 of 195 cases where DHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for DHR turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 30 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
DHR broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.078) is normal, around the industry mean (67.298). P/E Ratio (40.824) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (1.361) is also within normal values, averaging (3.473). Dividend Yield (0.007) settles around the average of (0.002) among similar stocks. P/S Ratio (5.900) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. DHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 77 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
BRKR | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 43 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 77 | |
PRICE GROWTH RATING 1..100 | 39 | 18 | |
P/E GROWTH RATING 1..100 | 57 | 54 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BRKR's Valuation (7) in the Medical Specialties industry is in the same range as DHR (15). This means that BRKR’s stock grew similarly to DHR’s over the last 12 months.
BRKR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as DHR (100). This means that BRKR’s stock grew similarly to DHR’s over the last 12 months.
DHR's SMR Rating (77) in the Medical Specialties industry is in the same range as BRKR (92). This means that DHR’s stock grew similarly to BRKR’s over the last 12 months.
DHR's Price Growth Rating (18) in the Medical Specialties industry is in the same range as BRKR (39). This means that DHR’s stock grew similarly to BRKR’s over the last 12 months.
DHR's P/E Growth Rating (54) in the Medical Specialties industry is in the same range as BRKR (57). This means that DHR’s stock grew similarly to BRKR’s over the last 12 months.
| BRKR | DHR | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 76% | 1 day ago 61% |
| Momentum ODDS (%) | 1 day ago 72% | 1 day ago 63% |
| MACD ODDS (%) | 1 day ago 70% | 1 day ago 64% |
| TrendWeek ODDS (%) | 1 day ago 73% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 75% | 1 day ago 58% |
| Advances ODDS (%) | 3 days ago 69% | 2 days ago 56% |
| Declines ODDS (%) | 10 days ago 74% | 10 days ago 59% |
| BollingerBands ODDS (%) | 1 day ago 77% | 1 day ago 59% |
| Aroon ODDS (%) | N/A | 1 day ago 57% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 1 FA rating(s) are green while DHR’s FA Score has 2 green FA rating(s).
- BRKR’s FA Score: 1 green, 4 red.
- DHR’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 6 TA indicator(s) are bullish while DHR’s TA Score has 3 bullish TA indicator(s).
- BRKR’s TA Score: 6 bullish, 2 bearish.
- DHR’s TA Score: 3 bullish, 4 bearish.
Price Growth
BRKR (@Medical/Nursing Services) experienced а +10.16% price change this week, while DHR (@Medical Specialties) price change was +2.61% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.92%. For the same industry, the average monthly price growth was -5.08%, and the average quarterly price growth was +38.31%.
Reported Earning Dates
BRKR is expected to report earnings on Feb 16, 2027.
DHR is expected to report earnings on Feb 03, 2027.
Industries' Descriptions
@Medical/Nursing Services (-2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-4.92% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BRKR and
Correlation & Price change
A.I.dvisor indicates that over the last year, BRKR has been closely correlated with A. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if BRKR jumps, then A could also see price increases.
| Ticker / NAME | Correlation To BRKR | 1D Price Change % | ||
|---|---|---|---|---|
| BRKR | 100% | +0.27% | ||
| A - BRKR | 78% Closely correlated | -0.52% | ||
| MTD - BRKR | 75% Closely correlated | -0.14% | ||
| WAT - BRKR | 68% Closely correlated | -0.97% | ||
| RVTY - BRKR | 68% Closely correlated | -0.53% | ||
| TMO - BRKR | 66% Loosely correlated | -0.07% | ||
More | ||||
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | -0.34% | ||
| TMO - DHR | 73% Closely correlated | -0.07% | ||
| RGEN - DHR | 68% Closely correlated | -0.78% | ||
| BIO - DHR | 64% Loosely correlated | -0.12% | ||
| A - DHR | 60% Loosely correlated | -0.52% | ||
| BRKR - DHR | 58% Loosely correlated | +0.27% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PBOT | 30.03 | 2.24 | +8.08% |
| Pictet AI & Automation ETF (PBOT) | |||
| UWM | 58.13 | 1.03 | +1.80% |
| ProShares Ultra Russell2000 (UWM) | |||
| MSBT | 21.39 | 0.29 | +1.37% |
| Morgan Stanley Bitcoin Trust ETF (MSBT) | |||
| FNDF | 53.88 | 0.22 | +0.41% |
| Schwab Fundamental International Equity ETF (FNDF) | |||
| PHDG | 40.87 | -0.29 | -0.70% |
| Invesco S&P 500 Downside Hedged ETF (PHDG) | |||